Literature DB >> 28750125

Demonstrating Noninferiority of Accelerated Radiotherapy With Panitumumab vs Standard Radiotherapy With Cisplatin in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma.

David Cheng1, Kyongsun Pak2, Lee-Jen Wei1.   

Abstract

Entities:  

Year:  2017        PMID： 28750125      PMCID： PMC7371341          DOI： 10.1001/jamaoncol.2017.0737

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  5 in total

1.  Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.

Authors:  Hajime Uno; Brian Claggett; Lu Tian; Eisuke Inoue; Paul Gallo; Toshio Miyata; Deborah Schrag; Masahiro Takeuchi; Yoshiaki Uyama; Lihui Zhao; Hicham Skali; Scott Solomon; Susanna Jacobus; Michael Hughes; Milton Packer; Lee-Jen Wei
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

2.  A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy.

Authors:  Brian Leyland-Jones; Igor Bondarenko; Gia Nemsadze; Vitaliy Smirnov; Iryna Litvin; Irakli Kokhreidze; Lia Abshilava; Mikheil Janjalia; Rubi Li; Kuntegowda C Lakshmaiah; Beka Samkharadze; Oksana Tarasova; Ranjan Kumar Mohapatra; Yaroslav Sparyk; Sergey Polenkov; Vladimir Vladimirov; Liang Xiu; Eugene Zhu; Bruce Kimelblatt; Kris Deprince; Ilya Safonov; Peter Bowers; Els Vercammen
Journal:  J Clin Oncol       Date:  2016-02-08       Impact factor: 44.544

3.  Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies.

Authors:  Hajime Uno; Janet Wittes; Haoda Fu; Scott D Solomon; Brian Claggett; Lu Tian; Tianxi Cai; Marc A Pfeffer; Scott R Evans; Lee-Jen Wei
Journal:  Ann Intern Med       Date:  2015-07-21       Impact factor: 25.391

4.  Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial.

Authors:  Lillian L Siu; John N Waldron; Bingshu E Chen; Eric Winquist; Jim R Wright; Abdenour Nabid; John H Hay; Jolie Ringash; Geoffrey Liu; Ana Johnson; George Shenouda; Martin Chasen; Andrew Pearce; James B Butler; Stephen Breen; Eric Xueyu Chen; T J FitzGerald; T J Childs; Alexander Montenegro; Brian O'Sullivan; Wendy R Parulekar
Journal:  JAMA Oncol       Date:  2017-02-01       Impact factor: 31.777

5.  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.

Authors:  Patricia Guyot; A E Ades; Mario J N M Ouwens; Nicky J Welton
Journal:  BMC Med Res Methodol       Date:  2012-02-01       Impact factor: 4.615
  5 in total
  4 in total

Review 1.  Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.

Authors:  Ambika Parmar; Michaelina Macluskey; Niall Mc Goldrick; David I Conway; Anne-Marie Glenny; Janet E Clarkson; Helen V Worthington; Kelvin Kw Chan
Journal:  Cochrane Database Syst Rev       Date:  2021-12-20

2.  Are restricted mean survival time methods especially useful for noninferiority trials?

Authors:  Boris Freidlin; Chen Hu; Edward L Korn
Journal:  Clin Trials       Date:  2021-02-24       Impact factor: 2.486

3.  Design of non-inferiority randomized trials using the difference in restricted mean survival times.

Authors:  Isabelle R Weir; Ludovic Trinquart
Journal:  Clin Trials       Date:  2018-08-03       Impact factor: 2.486

4.  A comparison of clinical outcomes between simultaneous integrated boost (SIB) versus sequential boost (SEQ) intensity modulated radiation therapy (IMRT) for head and neck cancer: A meta-analysis.

Authors:  Li Jiang; Yong Zhang; Zhendong Yang; Feifei Liang; Jiangtao Wu; Rensheng Wang
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.889
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.